R L Wortmann

Summary

Affiliation: University of Oklahoma Health Sciences Center
Country: USA

Publications

  1. ncbi Gout and hyperuricemia
    Robert L Wortmann
    Department of Internal Medicine, The University of Oklahoma College of Medicine, Tulsa 74135, USA
    Curr Opin Rheumatol 14:281-6. 2002
  2. ncbi Myotoxicity associated with lipid-lowering drugs
    Alan N Baer
    Division of Allergy, Immunology, and Rheumatology, Department of Medicine, University at Buffalo, SUNY, Erie County Medical Center, Buffalo, New York 14215, USA
    Curr Opin Rheumatol 19:67-73. 2007
  3. ncbi The clinical laboratory evaluation of the patient with noninflammatory myopathy
    R L Wortmann
    Department of Internal Medicine, The University of Oklahoma College of Medicine Tulsa, 4502 East 41st Street, Tulsa, OK, 74135, USA
    Curr Rheumatol Rep 3:310-6. 2001
  4. ncbi Lipid-lowering agents and myopathy
    Robert L Wortmann
    Department of Internal Medicine, The University of Oklahoma College of Medicine, Tulsa, 74135 2512, USA
    Curr Opin Rheumatol 14:643-7. 2002
  5. ncbi Treatment of acute gouty arthritis: one physician's approach and where this management stands relative to developments in the field
    Robert L Wortmann
    Department of Internal Medicine, The University of Oklahoma College of Medicine, 4502 East 41st Street, Tulsa, OK 74137, USA
    Curr Rheumatol Rep 6:235-9. 2004
  6. ncbi Recent advances in the management of gout and hyperuricemia
    Robert L Wortmann
    Department of Internal Medicine, University of Oklahoma College of Medicine, Tulsa, Oklahoma 74135, USA
    Curr Opin Rheumatol 17:319-24. 2005
  7. ncbi Advances in the management of gout and hyperuricaemia
    T K Hoskison
    Department of Internal Medicine, The University of Oklahoma College of Medicine-Tulsa, 4502 East 41st Street, Tulsa, OK 74135, USA
    Scand J Rheumatol 35:251-60. 2006
  8. ncbi Management of gout in older adults: barriers to optimal control
    Karl T Hoskison
    Department of Internal Medicine, The University of Oklahoma College of Medicine, Tulsa, Oklahoma 74135, USA
    Drugs Aging 24:21-36. 2007
  9. ncbi Differentiating idiopathic inflammatory myopathies from metabolic myopathies
    Robert L Wortmann
    Department of Internal Medicine, University of Oklahoma College of Medicine Tulsa, 4502 East 41st Street, Tulsa, OK 74137, USA
    Rheum Dis Clin North Am 28:759-78. 2002
  10. ncbi Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout
    Michael A Becker
    Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Arthritis Rheum 52:916-23. 2005

Detail Information

Publications14

  1. ncbi Gout and hyperuricemia
    Robert L Wortmann
    Department of Internal Medicine, The University of Oklahoma College of Medicine, Tulsa 74135, USA
    Curr Opin Rheumatol 14:281-6. 2002
    ..Uricosuric agents are also effective urate-lowering agents and provide an alternative to allopurinol. Strategies to treat patients who are sensitive to allopurinol continue to evolve...
  2. ncbi Myotoxicity associated with lipid-lowering drugs
    Alan N Baer
    Division of Allergy, Immunology, and Rheumatology, Department of Medicine, University at Buffalo, SUNY, Erie County Medical Center, Buffalo, New York 14215, USA
    Curr Opin Rheumatol 19:67-73. 2007
    ..Progress in our understanding of this form of myotoxicity is reviewed...
  3. ncbi The clinical laboratory evaluation of the patient with noninflammatory myopathy
    R L Wortmann
    Department of Internal Medicine, The University of Oklahoma College of Medicine Tulsa, 4502 East 41st Street, Tulsa, OK, 74135, USA
    Curr Rheumatol Rep 3:310-6. 2001
    ..Reports published in the past year have improved and expanded our understanding of the numerous noninflammatory myopathies and how these tools can be used more effectively...
  4. ncbi Lipid-lowering agents and myopathy
    Robert L Wortmann
    Department of Internal Medicine, The University of Oklahoma College of Medicine, Tulsa, 74135 2512, USA
    Curr Opin Rheumatol 14:643-7. 2002
    ..Consequently, the total dosage of lipid-lowering drug consumed, the concomitant use of other medications that affect their blood levels, and the individual's specific drug-metabolizing enzyme profile may contribute to this toxicity...
  5. ncbi Treatment of acute gouty arthritis: one physician's approach and where this management stands relative to developments in the field
    Robert L Wortmann
    Department of Internal Medicine, The University of Oklahoma College of Medicine, 4502 East 41st Street, Tulsa, OK 74137, USA
    Curr Rheumatol Rep 6:235-9. 2004
    ..These observations allow a better understanding of the mechanisms of action of these agents and provide the rationale for using them in combination in severe or refractory cases...
  6. ncbi Recent advances in the management of gout and hyperuricemia
    Robert L Wortmann
    Department of Internal Medicine, University of Oklahoma College of Medicine, Tulsa, Oklahoma 74135, USA
    Curr Opin Rheumatol 17:319-24. 2005
    ..To review the recent advances in the management of gout and hyperuricemia...
  7. ncbi Advances in the management of gout and hyperuricaemia
    T K Hoskison
    Department of Internal Medicine, The University of Oklahoma College of Medicine-Tulsa, 4502 East 41st Street, Tulsa, OK 74135, USA
    Scand J Rheumatol 35:251-60. 2006
    ..While patient education remains a cornerstone to ensure compliance, other quality indicators for the management of this disease have been reported and should guide the clinician in the treatment of gout and result in improved care...
  8. ncbi Management of gout in older adults: barriers to optimal control
    Karl T Hoskison
    Department of Internal Medicine, The University of Oklahoma College of Medicine, Tulsa, Oklahoma 74135, USA
    Drugs Aging 24:21-36. 2007
    ....
  9. ncbi Differentiating idiopathic inflammatory myopathies from metabolic myopathies
    Robert L Wortmann
    Department of Internal Medicine, University of Oklahoma College of Medicine Tulsa, 4502 East 41st Street, Tulsa, OK 74137, USA
    Rheum Dis Clin North Am 28:759-78. 2002
    ..These are essential factors in improving genetic counseling and eventually the therapy of these serious, and currently incurable, disorders...
  10. ncbi Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout
    Michael A Becker
    Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Arthritis Rheum 52:916-23. 2005
    ..0 mg/dl)...
  11. ncbi Febuxostat compared with allopurinol in patients with hyperuricemia and gout
    Michael A Becker
    University of Chicago Pritzker School of Medicine, Chicago, USA
    N Engl J Med 353:2450-61. 2005
    ..Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout...
  12. ncbi The management of gout: it should be crystal clear
    Robert L Wortmann
    J Rheumatol 33:1921-2. 2006
  13. ncbi Genetic risk factors associated with lipid-lowering drug-induced myopathies
    Georgirene D Vladutiu
    Department of Pediatrics, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, 936 Delaware Avenue, Buffalo, New York 14209, USA
    Muscle Nerve 34:153-62. 2006
    ..The effect of statins on energy metabolism combined with a genetic susceptibility to triggering of muscle symptoms may account for myopathic outcomes in certain high-risk groups...
  14. ncbi Dose-related statin myopathy: is it an issue?
    Robert L Wortmann
    Cleve Clin J Med 72:751-3, 756. 2005